Raf inhibitor Regorafenib, Purity ≥98%

Synonym: 755037-03-7; Regorafenib; BAY 73-4506; Stivarga; 4-(4-(3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-N-methylpicolinamide; Raf inhibitor

MDL: MFCD16038047
CAS Number: 755037-03-7
Compound CID: 11167602

Product Size

25 mg; 100 mg

Price

Datasheet

Datasheet

MSDS

MSDS

Properties

Description

Regorafenib, soluble in DMSO and insoluble in ethanol and water, blocks a MAPK/ERK signaling pathway. It targets B-Raf, B-Raf (V600E), B-Raf (V600E), Kit, Kit, Raf-1, RET, Tie-2, VEGFR1, VEGFR2, and VEGFR3.

Molecular Weight

482.8

Molecular Formula

C₂₁H₁₅ClF₄N₄O₃

Targets

B-Raf: 28 nM; B-Raf (V600E): 19 nM; B-Raf (V600E): 19 nM; Kit: 7 nM; Kit: 7 nM; Raf-1: 2.5 nM; RET: 1.5 nM; Tie-2: 311 nM; VEGFR1: 13 nM; VEGFR2: 4.2 nM; VEGFR3: 46 nM

Form

Lyophilized powder

Purity

≥98%

Solubility

DMSO: 88 mg/mL (182.26 mM); Water: Insoluble; Ethanol: Insoluble

Identity

Confirmed by NMR/HPLC/MS.

Stability

The product is stable for three years when stored at the recommended temperature in lyophilized powder.

Applications

Regorafenib can be employed to investigate its multi-kinase inhibition in cancer therapy.

Storage

Store at -20ºC.